Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the JAK2-STAT5 pathway in CML.

Literature DB >> 25170113

Targeting the JAK2-STAT5 pathway in CML.

Peter Valent¹.
1. MEDICAL UNIVERSITY OF VIENNA.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2014 PMID： 25170113 PMCID： PMC4148757 DOI： 10.1182/blood-2014-07-585943

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

10 in total

1. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors: Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal: Nat Chem Biol Date: 2012-01-29 Impact factor: 15.040

2. Janus kinase 2: a critical target in chronic myelogenous leukemia.

Authors: Ajoy K Samanta; Hui Lin; Tong Sun; Hagop Kantarjian; Ralph B Arlinghaus
Journal: Cancer Res Date: 2006-07-01 Impact factor: 12.701

3. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

Authors: Wolfgang Warsch; Karoline Kollmann; Eva Eckelhart; Sabine Fajmann; Sabine Cerny-Reiterer; Andrea Hölbl; Karoline V Gleixner; Michael Dworzak; Matthias Mayerhofer; Gregor Hoermann; Harald Herrmann; Christian Sillaber; Gerda Egger; Peter Valent; Richard Moriggl; Veronika Sexl
Journal: Blood Date: 2011-01-10 Impact factor: 22.113

4. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

Authors: S Xie; Y Wang; J Liu; T Sun; M B Wilson; T E Smithgall; R B Arlinghaus
Journal: Oncogene Date: 2001-09-27 Impact factor: 9.867

5. Jak2 is involved in c-Myc induction by Bcr-Abl.

Authors: Shanhai Xie; Hui Lin; Tong Sun; Ralph B Arlinghaus
Journal: Oncogene Date: 2002-10-17 Impact factor: 9.867

6. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Authors: A K Samanta; S N Chakraborty; Y Wang; H Kantarjian; X Sun; J Hood; D Perrotti; R B Arlinghaus
Journal: Oncogene Date: 2009-02-23 Impact factor: 9.867

7. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

Authors: Paolo Gallipoli; Amy Cook; Susan Rhodes; Lisa Hopcroft; Helen Wheadon; Anthony D Whetton; Heather G Jørgensen; Ravi Bhatia; Tessa L Holyoake
Journal: Blood Date: 2014-06-23 Impact factor: 22.113

8. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Authors: Min Chen; Paolo Gallipoli; Donna DeGeer; Ivan Sloma; Donna L Forrest; Matthew Chan; Damian Lai; Heather Jorgensen; Ashley Ringrose; Hui Mi Wang; Karen Lambie; Helen Nakamoto; Kyi Min Saw; Ali Turhan; Ralph Arlinghaus; James Paul; Jon Stobo; Michael J Barnett; Allen Eaves; Connie J Eaves; Tessa L Holyoake; Xiaoyan Jiang
Journal: J Natl Cancer Inst Date: 2013-02-27 Impact factor: 13.506

9. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.

Authors: Wolfgang Warsch; Eva Grundschober; Angelika Berger; Lars Gille; Sabine Cerny-Reiterer; Anca-Sarmiza Tigan; Andrea Hoelbl-Kovacic; Peter Valent; Richard Moriggl; Veronika Sexl
Journal: Oncotarget Date: 2012-12

10. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.

Authors: Liang L Zhou; Yun Zhao; Ashley Ringrose; Donna DeGeer; Erin Kennah; Ann E-J Lin; Guoqing Sheng; Xiao-Jiang Li; Ali Turhan; Xiaoyan Jiang
Journal: J Exp Med Date: 2008-10-20 Impact factor: 14.307

10 in total

9 in total

Review 1. The Philadelphia chromosome in leukemogenesis.

Authors: Zhi-Jie Kang; Yu-Fei Liu; Ling-Zhi Xu; Zi-Jie Long; Dan Huang; Ya Yang; Bing Liu; Jiu-Xing Feng; Yu-Jia Pan; Jin-Song Yan; Quentin Liu
Journal: Chin J Cancer Date: 2016-05-27

Review 2. Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.

Authors: Fabrizio Tabbò; Marco Pizzi; Peter W Kyriakides; Bruce Ruggeri; Giorgio Inghirami
Journal: Oncotarget Date: 2016-05-03

3. Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway.

Authors: Yanfei Jia; Yan Qi; Yunshan Wang; Xiaoli Ma; Yihui Xu; Jun Wang; Xiaoqian Zhang; Meihua Gao; Beibei Cong; Shuyi Han
Journal: Cancer Cell Int Date: 2019-01-08 Impact factor: 5.722

4. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.

Authors: Xuefei Wang; Jianling Yang; Guijie Guo; Riyue Feng; Ke Chen; Yuan Liao; Lianfeng Zhang; Liping Sun; Shile Huang; Ji-Long Chen
Journal: Mol Cancer Date: 2019-04-08 Impact factor: 27.401

5. Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review.

Authors: Georgio Medawar; Joseph Chahrouri; Rabih Said
Journal: Case Rep Rheumatol Date: 2019-05-27

Review 6. Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy.

Authors: Emanuela Andretta; Caterina Costa; Consiglia Longobardi; Sara Damiano; Antonio Giordano; Francesco Pagnini; Serena Montagnaro; Massimiliano Quintiliani; Chiara Lauritano; Roberto Ciarcia
Journal: Front Oncol Date: 2021-12-15 Impact factor: 6.244